HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Christian Hölscher Selected Research

liraglutide

10/2015Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice.
11/2014Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
4/2014Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
2/2014Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress.
2/2014The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease.
1/2014Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
1/2013The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain.
1/2013Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model.
4/2011The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Christian Hölscher Research Topics

Disease

28Alzheimer Disease (Alzheimer's Disease)
01/2016 - 01/2005
13Amyloid Plaque
01/2016 - 04/2011
11Inflammation
01/2016 - 01/2010
9Parkinson Disease (Parkinson's Disease)
02/2016 - 04/2014
6Neurodegenerative Diseases (Neurodegenerative Disease)
01/2016 - 06/2008
3Insulin Resistance
02/2016 - 05/2012
2Hypokinesia (Bradykinesia)
02/2016 - 12/2015
2Stroke (Strokes)
04/2014 - 10/2012
2Obesity
07/2013 - 05/2012
2Type 2 Diabetes Mellitus (MODY)
02/2013 - 06/2008
1Brain Ischemia (Cerebral Ischemia)
01/2016
1Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
01/2016
1Pathologic Processes
01/2015
1Neuroblastoma
02/2014
1Atrophy
07/2013
1Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
10/2012
1Body Weight (Weight, Body)
04/2011
1Amyloidosis
09/2006
1Gliosis
09/2006

Drug/Important Bio-Agent (IBA)

17Glucagon-Like Peptide 1 (GLP 1)IBA
01/2016 - 06/2008
13Insulin (Novolin)FDA Link
02/2016 - 06/2008
11Amyloid (Amyloid Fibrils)IBA
02/2014 - 01/2005
9liraglutideFDA Link
10/2015 - 04/2011
7IncretinsIBA
02/2016 - 01/2012
6HormonesIBA
02/2016 - 09/2010
5Glucose (Dextrose)FDA LinkGeneric
02/2016 - 05/2012
41- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA
02/2016 - 10/2015
3exenatide (Byetta)FDA Link
10/2015 - 04/2014
3ZP10A peptideIBA
11/2014 - 02/2014
2gastric inhibitory polypeptide receptorIBA
01/2016 - 01/2016
2geniposideIBA
12/2015 - 01/2015
2Congo RedIBA
11/2014 - 02/2012
2Presenilin-1IBA
02/2014 - 02/2012
2glucagon-like peptide receptor (receptor, glucagon-like peptide)IBA
08/2011 - 12/2009
1OxyntomodulinIBA
10/2015
1Arginine (L-Arginine)FDA Link
01/2015
1Glyoxal (Ethanedial)IBA
02/2014
1Glucagon (Glukagon)FDA Link
01/2013
1Biological Markers (Surrogate Marker)IBA
01/2013
1Fluorescein (Funduscein)FDA LinkGeneric
01/2013
1gastric inhibitory polypeptide (3-42)IBA
05/2012
1Pro(3)- glucose-dependent insulinotropic polypeptideIBA
01/2012
1amyloid beta-protein (25-35)IBA
06/2008

Therapy/Procedure

1Chinese Traditional Medicine (Traditional Chinese Medicine)
12/2015
1Injections
11/2014
1Intraperitoneal Injections
01/2013